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ABSTRACT For the benefit of planning for the future care and treatment of people
infected with hepatitis C virus (HCV) and to help guide prevention and control
programs, data are needed on HCV seroprevalence and associated risk factors. We
conducted a cross-sectional sero-behavioral survey of injection drug users (IDU)
detained for mandatory rehabilitation during a police sweep of Tehran, Iran, in early
2006. During the study period, a consecutive sample comprising 454 of 499 (91.0%)
men arrested and determined to be IDU by urine test and physical examination
consented to a face-to-face interview and blood collection for HCV antibody testing.
Overall, HCV prevalence was 80.0% (95% confidence interval (CI) 76.2–83.6).
Factors independently associated with HCV infection included history of incarceration
(adjusted OR 4.35, 95% CI 1.88–10.08), age of first injection ≤25 years (OR 2.72,
95% CI 1.09–6.82), and history of tattooing (OR 2.33, 95% CI 1.05–5.17). HCV
prevalence in this population of IDU upon intake to jail was extremely high and
possibly approaching saturation. Findings support that incarceration is contributing to
the increased spread of HCV infection in Iran and calls for urgent increased availability
of HCV treatment, long-term preparation for the care of complications of chronic
infection, and rapid scale-up of programs for the primary prevention of parenterally
transmitted infections among drug users.
KEYWORDS HCV, Prevalence, Risk factors, Injection drug users
INTRODUCTION
Hepatitis C virus (HCV) infection is increasingly recognized as a major healthcare
problem throughout the world. The World Health Organization estimates
170 million people to be infected worldwide. Almost 85% of cases can become
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902chronic and experience serious long-term complications, such as hepatic cirrhosis or
carcinoma. Patients can remain symptom-free for a long time; for example, liver
disease may appear up to 20 or 30 years after the initial infection.
1–4
HCV infection is recognized as the most common blood-borne infection in
injection drug users (IDU). HCV prevalence can reach 30% to 60%
5–7 within a few
years of its ﬁrst appearance in a population of IDU and achieve greater than 90% in
a mature epidemic.
8 The main mode of HCV transmission among IDU is by sharing
injection equipment not limited to needle sharing alone.
9 Since prisons contain a
high proportion of IDU, HCV is usually more prevalent in incarcerated populations
than in the surrounding community.
5,6 In addition, prisons may foster further spread
of HCV due to injection within jail, increased sharing due to scarcity of clean
injection equipment, and the high prevalence of the virus among co-inmates.
10,11
Tattooing, a common practice in jails, is also an identiﬁed risk factor for HCV
infection.
12 Iran has started a number of harm reduction programs for tackling the
HIV, HBV, and HCV epidemic among IDUs. Methadone maintenance therapy and
needle-exchange programs have been established in many prisons. Likewise,
condom distribution exists, but it should be expanded. There are more than 60
triangular clinics (sexually transmitted infections, HIV/AIDS, drug abuse) across
Iran, but it is unclear how many of these have initiated needle-exchange
programs.
13,14
Knowledge of the prevalence and risk factors of HCV infection is essential for
short- and long-term public-health responses to prevent, control, treat, and mitigate
the impact of this increasingly common and serious infection. We, therefore,
assessed the prevalence of HCV infection and associated risk behaviors among IDU
upon intake to detention in Tehran, Iran.
METHODS
We conducted a cross-sectional survey of male IDU consecutively recruited upon
detention in Tehran, Iran, to measure the prevalence of HCV and associated risk
factors for infection. Police conducted a “sweep” of IDU in early 2006 at check
points in Tehran neighborhoods with high incidence of drug-related arrests and
petty crime. Men loitering in the areas were intercepted by police using a drug user
“proﬁle” of demographic characteristics and appearance. Men suspected of drug use
after questioning were sent to a temporary detention center. They were then
screened for drugs using a urine test and physically examined for injection marks by
an experienced drug-addiction physician. Those who were identiﬁed by urine screen
and exam as IDU were sent to a mandatory drug rehabilitation center for 12 weeks.
We consecutively offered detainees participation in our study upon arrival at the
mandatory rehabilitation center. After providing consent, a face-to-face structured
interview was conducted by a physician and included demographic information,
imprisonment history, and injecting practices ever in the past and during previous
incarcerations. Blood specimens were collected by a professional phlebotomist and
tested for HCV antibody by EIA (DiaSorin, Spain). Non-identifying codes were
used to record all data and to link laboratory test results to the questionnaires.
Data were analyzed using STATA (8.0). HCV point prevalence was calculated as
the number of HCV-positive individuals divided by the number of test results
overall and stratiﬁed by demographic characteristics, incarceration history, and
drug-use practices. “Decline to answer” and missing data for many questions
were coded as 1 = acknowledging behavior and 0 = not acknowledging behavior.
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infection. Variables associated with HCVin bivariate analysis at the p≤0.10 level were
included as potential independent predictors. The ﬁnal model retained those variables
associated with infection at the pG0.05 level.
No special privileges, money, or other incentives were given, and participation
was voluntary. Strict conﬁdentiality of data including laboratory results was
maintained with no results or other information released to the jail health or
justice/prison system. Referrals to care were made to the Tehran University Medical
School. The institutional review board of Tehran University of Medical Sciences
approved the study protocol.
RESULTS
The police detained a total of 499 male IDU during 12 weeks. Of these, 454 (91.0%)
consented to participate in the survey and were tested for HCV antibodies. The
majority (65.6%) were under 35 years old, were or had been married (39.6%
currently married, 21.7% divorced, 0.7% widowed), and did not complete high
school (81.1%).
Overall HCV prevalence was 80.0% (95% conﬁdence interval (CI) 76.2–83.6;
Table 1). When asked about prior testing for HCV, 37.7% reported that they were
tested and knew their previous result. Of these subjects, 96.7% stated they had HCV
infection (data not shown). There was a signiﬁcant association between age and
HCV (p=0.04), with prevalence already high at 67.2% among 17- to 24-year-olds
and increasing to 87.7% among those 45 years and older. Although years of drug
use was not associated with HCV infection, time engaging in injection achieved over
95% prevalence after 5 years. Moreover, there was a borderline association between
HCV infection and younger age of ﬁrst injection. Elevated HCV prevalence was
signiﬁcantly associated with reporting ever sharing injection equipment, history of
tattooing, and history of prior incarceration. No associations with HCV infection
were found with respect to marital status, Tehran residence, education level, or types
of drugs used. While history of prior incarceration was associated with HCV
infection (reported by 75.3%), we detected no associations with speciﬁc reported
behaviors while in jail (Table 2).
Entering all variables associated with HCV infection at the p≤0.10 level into a
multiple regression model and retaining those signiﬁcantly associated at pG0.05
identiﬁed three independent predictors: history of prior incarceration (adjusted odds
ratio (AOR) 4.35, 95% CI 1.88–10.08), age of ﬁrst injection by 25 years of age (AOR
2.72, 95% CI 1.09–6.82), and history of tattooing (AOR 2.33, 95% CI 1.05–5.17).
DISCUSSION
HCV infection in our consecutive sample of IDU on entry into detention was
astonishingly high: four-ﬁfths were infected overall; nearly 90% were infected by
age 45 years and over 95% after 5 years of injection. Our estimates are among the
highest in the world and, to our knowledge, the highest recorded in Iran to
date.
15–18 For example, in the late 1990s, HCV prevalence among drug-using
prisoners in Hammadan, Iran, was 7.3% with higher prevalence among IDU.
17 In
2001 in Zanjan, Iran, HCV prevalence was measured at 47.7% among 346 drug-
addict prisoners.
18 HCV prevalence was measured at 60% among incarcerated IDU
in Mashhad, Iran, 4 years earlier than our survey.
16 These studies point to a
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Variable
N
a HCV + HCV seroprevalence %
(%) (N) (95% CI)
Total 454 (100) 363 80.0 (76.2–83.6)
Age group*
17–24 years 61 (13.8) 41 67.2 (54.0–78.7)
25–34 years 229 (51.8) 185 80.8 (75.1–85.7)
35–44 years 103 (23.3) 85 82.5 (73.8–89.3)
≥45 years 49 (11.1) 43 87.7 (75.2–95.4)
Marital status
Single 168 (38.0) 133 79.2 (72.2–85.0)
Married 175 (39.6) 141 80.6 (73.9–86.1)
Divorced 96 (21.7) 77 80.2 (70.8–87.6)
Widowed 3 (0.7) 3 100.0 (29.2–100.0)
b
Residence
Outside of Tehran 71 (16.2) 60 84.5 (74.0–92.0)
Tehran 367 (83.8) 292 79.6 (75.1–83.6)
Education level:
Illiterate 30 (6.8) 23 76.7 (57.7–90.1)
Did not complete high school 326 (74.3) 265 81.3 (76.6–85.4)
Completed high school or higher 83 (18.9) 63 75.9 (66.3–84.6)
Drugs reported ever used (local name)
Opium (taryak) 360 (79.3) 287 79.7 (75.2–83.7)
Boiled opium resin (shireh) 100 (22.0) 83 83.0 (74.2–89.8)
Opium resin (sookteh) 82 (18.1) 68 82.9 (73.0–90.3)
Heroin 334 (73.6) 273 81.7 (77.2–85.7)
“Crack” (purer form of heroin) 71 (15.6) 52 73.2 (61.4–83.1)
Hashish 131 (28.9) 102 77.9 (69.8–84.6)
Bupenorphine (norgeezak) 436 (96.0) 346 79.4 (75.2–83.1)
Bupenorphine + steroids (afzoor) 9 (2.0) 8 88.9 (51.7–99.7)
Methamphetamine (crystal) 18 (4.0) 12 66.7 (41.0–86.7)
Morphine 11 (2.4) 7 63.6 (30.8–89.1)
Other drug 59 (13.0) 47 79.7 (67.2–89.0)
Years of drug use
Up to 1 year 26 (11.7) 21 80.8 (60.6–93.4)
2 to 5 years 69 (30.9) 56 81.2 (69.9–89.6)
More than 5 years 128 (57.4) 108 84.4 (78.0–90.7)
Years of injection**
Up to 1 year 77 (39.5) 55 71.4 (60.0–81.1)
2 to 5 years 72 (36.9) 62 86.1 (75.9–93.1)
More than 5 years 46 (23.6) 44 95.6 (85.2–99.5)
Age of ﬁrst injection ≤25 years old*** 73 (37.4) 65 89.0 (79.5–95.1)
Reported ever sharing needles 58 (12.8) 49 84.5 (72.6–92.6)
Reported ever sharing injection equipment* 119 (26.2) 104 87.4 (80.1–92.8)
Reported ever sharing needles or equipment* 123 (27.1) 106 86.2 (78.8–91.7)
Reported past history of incarceration**** 342 (75.3) 285 83.3 (79.0–87.1)
Reported history of using an opioid in jail 85 (18.7) 73 85.9 (76.6–92.5)
Reported history of injection in jail 30 (6.6) 27 90.0 (73.5–97.9)
History of using shared materials in jail 28 (6.2) 25 89.3 (71.8–97.7)
History of using sharp objects in jail 112 (24.7) 95 84.8 (76.8–90.9)
Reported past access to new syringes in jail 313 (68.9) 246 78.6 (73.6–83.0)
History of tattooing**** 125 (27.5) 111 66.7 (41.0–86.7)
aSubgroups do not always add up to total due to missing data
bOne-sided 97.5% CI
*p≤0.05, **p≤0.001, ***p≤0.10, ****p≤0.01
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current study.
8
Not only do our data speak to a catastrophic future burden of disease and
health care need due to HCV but they also serve as an indicator of the potential
spread of HIV. Both infections have similar routes of transmission through injection
practices, but because HCV is more infectious, it acts as a biological marker or
herald for future HIV transmission. Given the near saturation of HCV infection in
our study after a few years of injection, HIV infection may already be at a peak
among IDU in Iran—and especially among IDU with exposure to incarceration.
Our study corroborates the potential role that incarceration plays in propagat-
ing HCV, with prior history of incarceration imparting a fourfold increased risk.
This result is consistent with multiple studies around the world that also ﬁnd
incarceration associated with HCV infection and with the injection-related practices
that lead to HCV infection.
16–24 In addition, it is possible for non-injection drug
users to be at elevated risk for HCV due to incarceration,
19,25,26 either through
modes of transmission other than sharing injection equipment or because persons
smoking opium may resort to injection while in jail due to the scarcity of raw opium
and the inability to hide smoking. Of note, our data show that opium use is quite
high among this population. Moreover, Iran has one of the highest per capita rates
of opioid use in the world.
18 Thus, in the Iranian context, incarceration of drug
users may be particularly detrimental to controlling the spread of HCV. We also
found that history of tattooing, a practice also common to incarcerated populations,
was an independent risk factor for HCV infection.
18,27–29 In the abovementioned
study of prisoners in Zanjan, tattooing was also associated with HCV positivity
among prisoners.
18
Of note, we did not ﬁnd a direct association between HCVand the reporting of
speciﬁc practices while in jail, only the global indicator of past incarceration. This
may be due to bias in underreporting of illegal behaviors while in the jail setting.
Other limitations of this study include the mismatch between recall time period and
potential exposure, the reliability of other responses in the jail setting, and the
representativeness of the sample to all IDU. Also, there was no conﬁrmatory test for
HCV. We believe, however, that these factors are not likely to change the conclusion
of high HCV prevalence among IDU in Tehran.
The extremely high rate of HCV in this population presents dismaying
challenges for Iran. Programs for the future care of HCV-infected persons will need
to be scaled up rapidly. One front to address is the timely screening of persons at
risk, the early identiﬁcation of persons infected, and the provision of effective
treatment, hopefully to bring about cure. These measures are relatively expensive
and currently not widely available in Iran. We hope our data will help advocate for
expanding the opportunities for the diagnosis and treatment of HCV. The jail
system, through which many drug-users pass, is one point to enhance HCV
TABLE 2 Independent associations of HCV infection among injection drug users upon
detention, Tehran, Iran, 2006
Model Adjusted OR (95%CI) P value
History of prior incarceration 4.35 (1.88–10.08) 0.001
Age of ﬁrst injection ≤25 years old 2.72 (1.09–6.82) 0.032
History of tattooing 2.33 (1.05–5.17) 0.037
P. KHEIRANDISH ET AL. 906programs. Drug-treatment programs are another. The healthcare system of Iran will
also have to prepare itself for the long-term consequences of HCV infection,
including liver carcinoma and failure. Primary prevention may be even more
challenging, not least because the prevalence of infection is already so high.
Nonetheless, there will likely be future generations of as yet uninfected young drug
users for whom increased harm-reduction programs, including needle exchange and
methadone maintenance, will be needed to avert further disaster.
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